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To investigate superficial retinal microvascular plexuses detected by optical coherence
tomography angiography (OCT-A) in multiple sclerosis (MS) subjects and compare them
with healthy controls.
Methods
A total of 92 eyes from 92 patients with relapsing-remitting MS and 149 control eyes were
included in this prospective observational study. OCT-A imaging was performed using Triton
Swept-Source OCT (Topcon Corporation, Japan). The vessel density (VD) percentage in
the superficial retinal plexus and optic disc area (6 x 6 mm grid) was measured and com-
pared between groups.
Results
MS patients showed a significant decrease VD in the superior (p = 0.005), nasal (p = 0.029)
and inferior (p = 0.040) parafoveal retina compared with healthy subjects. Patients with dis-
ease durations of more than 5 years presented lower VD in the superior (p = 0.002), nasal (p
= 0.017) and inferior (p = 0.022) parafoveal areas compared with healthy subjects. Patients
with past optic neuritis episodes did not show retinal microvasculature alterations, but
patients with an EDSS score of less than 3 showed a significant decrease in nasal (p =
0.024) and superior (p = 0.006) perifoveal VD when compared with healthy subjects.
Conclusions
MS produces a decrease in retinal vascularization density in the superficial plexus of the
parafoveal retina. Alterations in retinal vascularization observed in MS patients are indepen-
dent of the presence of optic nerve inflammation. OCT-A has the ability to detect subclinical
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vascular changes and is a potential biomarker for diagnosing the presence and progression
of MS.
Introduction
Multiple sclerosis (MS) is a chronic inflammatory demyelinating autoimmune disease of the
central nervous system with axonal degeneration being the main determinant of neurological
disability. The etiology is unknown and the course of MS cannot be predicted. Some patients
are minimally affected by the disease while in others MS progresses quickly towards total dis-
ability. Symptoms of MS will depend on the damaged area and the phenotype. Patients with
the relapsing-remitting (RRMS) phenotype suffer symptoms in the form of outbreaks, which
can last days or even months, and usually disappear leaving functional sequelae. Some of the
most common symptoms are blurred or double vision, muscular weakness, loss of dexterity,
numbness or tingling and pain [1,2].
Examination of patients with MS has shown that abnormalities found in the central nervous
system are also widespread in the neuro-retina. The visual afferent pathway, from the retina to
the visual cortex, is one of the most affected systems, which underlines the importance of
studying the visual pathway as a source of potential biomarkers in MS. Inflammation, demye-
lination and axonal degeneration in the afferent visual pathway are the main cause of visual
symptoms in MS.
In recent years, optical coherence tomography (OCT) has demonstrated its ability as a non-
invasive way of monitoring neurodegenerative diseases (such as MS, Parkinson’s or Alzhei-
mer’s) based on quantification of axonal loss in the retina [3–6]. With this technique, the visual
pathway is recognized as a model for correlating retinal neurodegeneration and disability in
MS and some authors have demonstrated its potential as an early diagnostic tool [7]. In addi-
tion, the latest OCT software provides measurements of each retinal layer and even measure-
ments of the choroidal plexus, which seems to provide more accurate measurements of axonal
damage and ischemic processes [8–10].
Current diagnostic methods are evolving very rapidly. However, there is still a large time
lapse between the first outbreak of the disease and definitive diagnosis. Early diagnosis is
related to treatment prescription and therefore a good prognosis for the disease. OCT is a pain-
less, innocuous, and non-invasive imaging test capable of providing high-quality images of the
different layers of the retina. In the last 5 years, and due to the high definition of the acquired
images, OCT has become able to determine the existence of vascular density (VD) by analyzing
contrast in images of blood cells in movement [11]. This finding makes it possible to quickly
and easily obtain a 3D cube containing the vascular structures of the retina and the choroid
without the need for contrast injection. Based on the results of previous studies on MS and ret-
inal/choroidal vessel density it has been suggested that MS patients show retinal vascular alter-
ations [12–14]. However, research into the use of OCT-A in this field is still scarce [15,16].
This study aims to analyze retinal VD in patients with MS using optical coherence tomography
angiography (OCT-A).
Material andmethods
All procedures in this study adhered to the tenets of the Declaration of Helsinki; the experi-
mental protocol was approved by the Ethics Committee of the Miguel Servet Hospital
(CEICA), and all participants provided written informed consent to participate in the study.
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Based on a preliminary study conducted by our group, we calculated the sample size needed
to detect differences of at least 5 μm in the thickness of the CFNR measured by OCT [3], apply-
ing a bilateral test with risk α of 5% and risk β of 10% (i.e. with a power of 90%). In order to
obtain enough sample of patients with MS, which would allow us to study in depth the natural
history of the disease, the non-exposed/exposed ratio was determined to be 0.5. With these
data it was concluded that at least 146 eyes would be necessary (73 from healthy subjects and
73 from MS patients). We included more subjects in both groups to improve power of the
study.
The study group included only patients with the relapsing-remitting multiple sclerosis phe-
notype. MS was diagnosed on the basis of the 2010 revision of the McDonald Criteria and was
confirmed by a neurologist specializing in MS [17]. The control group consisted of subjects
who did not have any type of relevant ocular (epiretinal membranes, glaucoma, age related
macular disease etc) or systemic disease previous were related with retinal vascular density
such as Diabetes mellitus, arterial hypertension etc. Subjects with visual acuity < 0.4 decimal
(6/15 on the Snellen chart), intraocular pressure > 20 mmHg, refractive errors greater than 5
diopters of spherical equivalent refraction or 3 diopters of astigmatism and/or active MS flare
(of any neurological deficit) in the 6 months prior to enrollment in the study were excluded
from the study. Active MS flare was considered a reason for exclusion because acute axonal
loss or neuro-retinal edema could mask neuronal damage secondary to MS progression (i.e.,
chronic neurodegeneration) or modify retinal VD, which were the main targets of this study.
The previous neurological ophthalmological examination was used to detect ocular impair-
ments such as glaucoma, cataract or media opacity that could affect functional vision or retinal
microvascularization. During 12 months all subjects were evaluated for best-corrected visual
acuity (BCVA), pupillary reflexes, ocular motility, anterior segment examinations, intraocular
pressure (IOP) using the Goldmann applanation tonometer, and papillary morphology by fun-
duscopy. Subjects with ocular disease or prior ocular surgery were excluded.
Neurological and ophthalmological examinations were performed less than 3 months
before OCT-A data acquisition.
Evaluation of best-corrected visual acuity was performed using the ETDRS optotype, com-
posed of retro-illuminated sheets under photopic light conditions. Patients were seated at a
4-meter distance from the test and best correction was applied until the best possible visual
acuity was achieved. The BCVA was expressed in LogMAR. Contrast sensitivity was measured
using the Pelli Robson test. This test consists of 6 letters on each line and contrast varies from
major to minor. Each line has two different groups, and triplets of letters have the same con-
trast. It uses a unique spatial frequency of 1 cycle/degree. The test was performed in monocular
mode and with the subject at a distance of 1 meter.
Swept-source optical coherence tomography (SS-OCT) (Triton plus; Topcon Corporation,
Tokyo, Japan) coupled with non-invasive OCT angiography technology (SS-OCT Angio™) was
used to obtain the retinal images. The Topcon SS-OCT uses a tunable laser as a light source to
provide a 1050 nm-centered wavelength. This device reaches a scanning speed of 100,000 A-
scans per second. Because of this, Topcon SS-OCT visualizes the deepest structures of the ret-
ina, detecting even low microvascular density with high sensitivity [18]. All measurements
were taken by a single observer, and only images with signal strength index (SSI) and analyzed
images with quality score above 50 and 40 respectively [19] were included and also images
with movement artefacts were excluded from the analysis.
SS-OCT Angio™ images were acquired using a 6 x 6 mm cube—one cube centered on the
fovea and the other centered on the optic disc—with a resolution of 320 x 320. Surface area
(SA) was measured using Topcon IMAGEnet1 (version 1.19) proprietary software after auto-
mated segmentation of the macular area into superficial vascular plexuses (SVP) (SVP-FAZ)
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including large vessels. Vessel density values were calculated from the internal limiting mem-
brane to the inner plexiform layer. VD refers to the surface, measured in mm2, which limits
the cube in which erythrocyte movement is detected. This software interprets the vascular den-
sity of the blood vessels in the scanning area (6 x 6 mm) as the percentage of that area that is
occupied by the lumens of the vessels. It provides an ETDRS circular grid (3 mm diameter)
which delivers a VD percentage in each of the sections that compose this grid. The grid cen-
tered on the fovea divides the macular region into the central foveal area and a perifoveal ring
divided into the superior, inferior, nasal and temporal sections. The same grid is transferred to
the center of the pit in the optic disc (Fig 1).
Finally, following the Advised Protocol for OCT Study Terminology and Elements (APOS-
TEL) recommendations for reporting quantitative OCT studies, our study was performed
using only one eye in MS patients (randomly selected), except in those patients in which only
one eye had a history of optic neuritis (in these cases, both eyes were included in the analysis
and were treated as independent) [20].
The neurological evaluation in the MS group included the Expanded Disability Status Scale
(EDSS) [21] score, designed by John Kurtzke, which measures patients’ functional disability
and classifies it into specific ranges that indicate the level of disability presented by the patient:
0–3.5 mild; 4–6 moderate; 7–8 severe; 8.5–9.5 very severe; and 10 death. We also categorized
disease duration, prescribed treatments, prior episodes of optic neuritis, and quality of life
(QoL) using the multiple sclerosis quality-of-life score (MSQoL-54). This questionnaire is
based on a generic survey (the RAND 36-Item Health 1.0) with 18 additional MS-specific
items. It consists of a total of 54 items: 52 spread across 12 dimensions (physical health, limita-
tions due to physical problems, limitations due to emotional problems, pain, emotional well-
being, energy, perception of health, social function, cognitive function, concern for health,
quality of life as a whole, sexual function) plus 2 individual items that measure the change in
health status (comparison of current health with that of a year ago) and satisfaction with sexual
function. The dimensions are scored from 0 to 100, where a higher value indicates better
Health-Related Quality of Life. In addition, two subtotals of mental and physical health are
obtained. The MSQoL-54 has been shown to offer good internal consistency, reliability and
theoretical validity [22–25].
Fig 1. Image of angiography optical coherence tomography measured in 6x6mm area in superficial vascular plexus with gird centered in macula. Left image shows
a B-scan with orange lines limiting analyzed zone. Right image shows density map with gird divided in five areas; central, nasal, interior, temporal and superior with
number of percentages of vessel density.
https://doi.org/10.1371/journal.pone.0243236.g001
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Statistical analysis: All data studied were recorded in an Excel database and analyzed using
the IBM-SPSS statistical package (SPSS Inc, Chicago, IL, USA, version 20.0). The Kolmogo-
rov-Smirnov test showed that most of the study variables were not normally distributed. Thus,
non-parametric tests were used in our analysis. Comparison between MS patients and control
subjects was performed using the Mann Whitney U test. Differences between groups were ana-
lyzed using a one-way ANOVA and a Games-Howell post hoc test and significance was set at
p< 0.05. To avoid a high false positive rate, the Bonferroni correction for multiple tests was
calculated and the corrected p values were added to the previously calculated data (see Tables).
Results
The study group comprised 149 eyes of healthy subjects (20 males and 129 females) and 92
eyes of MS patients (12 males and 80 females). The average age of the sample was 41.76 ± 16.23
years, with no age differences existing between groups (p = 0.955) (Table 1).
MSQoL-54 was completed by 20 MS patients. The scores on the various functional quality-
of-life evaluation scales are shown in Table 2.
The structural analysis performed using OCT-A revealed a higher vascular density in the
peripapillary area in both groups when compared with the perimacular area. It is necessary to
consider that retinal vasculature has some anatomical variations sensitive to axial length,
refraction, age. . . [26], which causes variability in vascular density values. Fig 2 show VD val-
ues in control group and EM group related with age (Fig 2).
The MS group showed significant thinning in the ETDRS nasal macular area (p = 0.029),
superior macular area (p = 0.005) and inferior macular area (p = 0.040) and a significant
reduction in contrast sensitivity (p = 0.008) compared with the control group. Superior macu-
lar area remains minimally significantly low vascular density in EM groups despite removing
the outlier data (p = 0.047) (Table 3) (Fig 3).
A lower vascular density tendency is observed in the group of MS patients, with significance
existing in the nasal, inferior and superior macular areas.
Analysis by subgroup
Analysis by subgroup was performed on the sample of MS patients based on disease duration,
existence or otherwise of previous episodes of optic neuritis and degree of functional
impairment by the disease.
Table 1. Baseline characteristics of the subjects included in the study.
CONTROL MS P
N (eyes) 149 92 -
Eye -
Right eye (%) 79 (53) 46 (50)
Left eye (%) 70 (47) 46 (50)
Sex -
Female (%) 129 (86.6) 80 (87)
Male (%) 20 (13.4) 12 (13)
Age (years) 41.81 ± 18.36 41.70 ± 12.11 -
IOP (mmHg) 15.15 ± 1.57 15.37 ± 2.04 0.959
EDSS - 2.02 ± 1.43 0.359
Abbreviations: MS, multiple sclerosis; N, number of eyes; IOP, Intraocular pressure; EDSS, Expanded Disability Status Scale.
https://doi.org/10.1371/journal.pone.0243236.t001
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To analyze disease duration, one subgroup was created containing patients diagnosed with
MS less than or equal to 5 years earlier (44 eyes) and another subgroup was created with
patients diagnosed with MS more than 5 years earlier (48 eyes). No significant differences in
age, sex or IOP levels were found between the two subgroups. ANOVA analysis with a post hoc
Games-Howell test found a significant decrease in the nasal macular area (p = 0.001), inferior
macular area (p = 0.003) and superior macular area (p < 0.001) in the group that had had the
disease for more than 5 years when compared with the healthy subjects. Also, without outliers,
superior area macular has a decreased vascular density in EM group. There was also a decrease
in contrast sensitivity in both MS groups when compared with healthy subjects (p = 0.026 and
p = 0.041) (Table 4).
Two subgroups were also analyzed in the patient group: subgroup MS+ON comprising
eyes of patients with a history of optic neuritis, and subgroup MS-ON comprising eyes that
had never suffered an episode of neuritis. The post hoc analysis indicated a significant decrease
in vascular in the nasal and superior macular areas in the MS+ON group in comparison with
the control group (p = 0.015, p = 0.033) and in the MS-ON group in comparison with the con-
trol group (p = 0.019, p = 0.009). Lower contrast sensitivity was observed in the subgroup with
a history of neuritis when compared with the control group (p = 0.004) and with the group of
patients with no history of ON (p = 0.036) (Table 5).
Based on the score on the Expanded Disability Status Scale, patients were divided into two
groups: one group with EDSS scores of less than 3 and another group with EDSS scores equal
to or greater than 3. The ANOVA test and the post hoc Games-Howell test for non-parametric
tests showed levels of contrast sensitivity and vascular density (nasal macular area, p = 0.003;
superior macular area, p = 0.001) that were significantly lower in the group with EDSS scores
of less than 3 than among the healthy subjects. However, no differences were observed between
the two EDSS groups (Table 6).
The correlation between the EDSS score and quality-of-life questionnaire values was ana-
lyzed using Spearman’s correlation test, revealing a significant negative correlation between
Table 2. Mean and standard deviation of MSQoL-54 values in MS patients.
MS group









HEALTH PERCEP 45.29 23.65
ENERGY 48.08 27.86
PHYSICAL LIMIT 43.70 42.67
PAIN 60.73 32.10




SEX SATISF 70.00 29.91
https://doi.org/10.1371/journal.pone.0243236.t002
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the mental quality-of-life (-0.478), physical limitations (-0.467) and perceived change in com-
parison with the year before (-0.455). A strongly significant negative correlation was also
observed between the EDSS score and physical quality-of-life (Spearman’s Correlation p =
-0.623) (Table 7).
In addition, the correlation between the EDSS score and VD was analyzed, revealing a nega-
tive correlation (-0.271) in VD in the nasal area of the optic disc. (Table 8) and a positive corre-
lation between the inferior VD area of the optic disc and the questions related to mental state
in general (Spearman’s correlation p = 0.503).
Fig 2. Scatterplot graphic of vascular density and age in control group and MS group.
https://doi.org/10.1371/journal.pone.0243236.g002
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Table 3. Mean and standard deviation of vascular density. Average of the vascular density of the four macular quadrants. Best-corrected visual acuity and contrast sensi-
tivity in each group, and significance.
CONTROLS MS P
Mean ± Std. deviation / (without outliers) Mean ± Std. deviation / (without outliers) P / (without outliers)
BCVA 0.05 ± 0.07 0.04 ± 0.08 0.447
Contrast sensitivity 1.86 ± 0.13 1.75 ± 0.15 0.008�
Vascular density (%) Central macula 21.89 ± 4.80 / 21.78 ± 3.99 21.45 ± 4.51 / 21.47 ± 4.51 0.322 / 0.394
Nasal macula 48.21 ± 5.52 / 47.20 ± 3.13 46.50 ± 2.56 / 46.51 ± 2.57 0.029� / 0.104
Inferior macula 51.19 ± 5.8 / 49.84 ± 2.99 49.50 ± 3.50 / 49.53 ± 3.52 0.040� / 0.262
Temporal macula 48.24 ± 4.21 / 47.73 ± 3.21 47.26 ± 2.46 / 47.24 ± 2.45 0.158 / 0.292
Superior macula 51.53 ± 5.43 / 50.32 ± 3.17 49.51 ± 3.04 / 49.53 ± 3.05 0.005� / 0.047 �
Average 49.79 ± 4.72 48.21 ± 2.09 0.011�
Central disc 23.29 ± 12.80 / 23.32 ± 12.73 22.59 ± 11.61 / 22.58 ± 11.65 0.606 / 0.575
Nasal disc 57.98 ± 5.66 / 58.13 ± 5.46 57.28 ± 5.34 / 57.29 ± 5.35 0.173 / 0.136
Inferior disc 65.86 ± 6.27 / 65.97 ± 6.09 65.62 ± 7.83 / 65.65 ± 7.84 0.870 / 0.851
Temporal disc 55.18 ± 6.59 / 55.49 ± 5.15 55.57 ± 3.82 / 55.60 ± 3.79 0.964 / 0.992
Superior disc 64.23 ± 5.73 / 64.47 ± 5.41 64.21 ± 4.3 / 64.23 ± 4.32 0.379 / 0.342
Abbreviations: MS, multiple sclerosis; Std., standard; BCVA, best-corrected visual acuity. Asterisk marks significance based on Mann-Whitney test.
https://doi.org/10.1371/journal.pone.0243236.t003
Fig 3. Graphic of percentage of superficial plexus macular in both groups.
https://doi.org/10.1371/journal.pone.0243236.g003
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Table 4. Mean and standard deviation of vascular density. BCVA and contrast sensitivity in each group and significance in patients diagnosed with the disease less than
5 years earlier and in patients diagnosed with the disease more than 5 years earlier. Average of the vascular density of the four macular quadrants.
CONTROL MS� 5 years MS > 5years P
Mean ± Std. deviation / (without
outliers)
Mean ± Std. deviation / (without
outliers)




N 145 44 48
BCVA 0.05 ± 0.07 0.02 ± 0.05 0.06 ± 0.11 0.075
Contrast sensitivity 1.86 ± 0.13 1.75 ± 0.15 1.75 ± 0.15 0.029�
Vascular density
(%)
Central macula 21.89 ± 4.80 / 21.78 ± 3.99 22.35 ± 4.56 / 22.36 ± 4.58 20.62 ± 4.34 / 20.65 ± 4.32 0.165 / 0.125
Nasal macula 48.21 ± 5.52 / 47.20 ± 3.13 46.91 ± 2.59 / 46.95 ± 2.60 46.14 ± 2.50 / 46.10 ± 2.50 0.017� / 0.084
Inferior macula 51.19 ± 5.8 / 49.84 ± 2.99 50.15 ± 3.65 / 50.16 ± 3.70 48.90 ± 3.27 / 48.96 ± 3.27 0.022� / 0.155
Temporal
macula
48.24 ± 4.21 / 47.73 ± 3.21 47.72 ± 2.44 / 47.68 ± 2.43 46.83 ± 2.42 / 46.83 ± 2.42 0.065 / 0.177
Superior
macula
51.53 ± 5.43 / 50.32 ± 3.17 50.18 ± 2.69 / 50.20 ± 2.69 48.89 ± 3.24 / 48.92 ± 3.25 0.002� / 0.025�
Average 49.79 ± 4.72 48.74 ± 3.21 47.69 ± 3.52 0.014�
Central disc 23.29 ± 12.80 / 23.32 ± 12.73 23.47 ± 12.16 / 23.50 ± 12.21 21.68 ± 11.06 / 21.62 ± 11.11 0.735 / 0.708
Nasal disc 57.98 ± 5.66 / 58.13 ± 5.46 57.57 ± 4.86 / 57.61 ± 4.86 56.97 ± 5.85 / 56.95 ± 5.86 0.577 / 0.448
Inferior disc 65.86 ± 6.27 / 65.97 ± 6.09 66.96 ± 5.27 / 66.98 ± 5.25 64.22 ± 9.70 / 64.26 ± 9.72 0.175 / 0.168
Temporal disc 55.18 ± 6.59 / 55.49 ± 5.15 56.49 ± 3.68 / 56.57 ± 3.64 54.61 ± 3.78 / 54.60 ± 3.73 0.277 / 0.146
Superior disc 64.23 ± 5.73 / 64.47 ± 5.41 64.69 ± 4.31 / 64.70 ± 4.40 63.71 ± 4.28 / 63.74 ± 4.24 0.687 / 0.636
Abbreviations: MS, multiple sclerosis; Std., standard; BCVA, best-corrected visual acuity. Asterisk marks significance based on ANOVA and posterior post hoc Games-
Howell test.
https://doi.org/10.1371/journal.pone.0243236.t004
Table 5. Mean and standard deviation of vascular density. Average of the vascular density of the four macular quadrants. Best-corrected visual acuity and contrast sensi-
tivity in MS group with past optic neuritis (MS+ON) and MS group without optic neuritis (MS-ON).
CONTROL MS-ON MS+ON P
Mean ± Std. deviation / (without
outliers)
Mean ± Std. deviation / (without
outliers)




N 151 72 20
BCVA 0.05 ± 0.07 002 ± 0.06 0.07 ± 0.12 0.177
Contrast sensitivity 1.83 ± 0.14 1.78 ± 0.15 1.68 ± 0.11 0.016�
Vascular density
(%)
Central macula 21.89 ± 4.80 / 21.78 ± 3.99 21.60 ± 4.81 / 21.62 ± 4.82 20.80 ± 3.62 / 20.80 ± 3.59 0.683 / 0.697
Nasal macula 48.21 ± 5.52 / 47.20 ± 3.13 46.65 ± 2.45 / 46.66 ± 2.46 46.15 ± 1.95 / 46.13 ± 1.92 0.046� / 0.305
Inferior macula 51.19 ± 5.8 / 49.84 ± 2.99 49.74 ± 3.74 / 49.79 ± 3.76 48.56 ± 2.77 / 48.53 ± 2.75 0.053 / 0.336
Temporal
macula
48.24 ± 4.21 / 47.73 ± 3.21 47.32 ± 2.57 / 47.31 ± 2.56 47.00 ± 2.20 / 46.93 ± 2.22 0.147 / 0.464
Superior
macula
51.53 ± 5.43 / 50.32 ± 3.17 49.73 ± 3.01 / 49.75 ± 3.04 48.78 ± 3.37 / 48.87 ± 3.27 0.012� / 0.193
Average 49.79 ± 4.72 48.39 ± 2.15 47.61 ±2.06 0.021�
Central disc 23.29 ± 12.80 / 23.32 ± 12.73 21.05 ± 10.87 / 21.03 ± 10.95 22.32 ± 10.46 / 22.33 ± 10.35 0.281 / 0.265
Nasal disc 57.98 ± 5.66 / 58.13 ± 5.46 58.10 ± 5.06 / 58.12 ± 5.06 55.60 ± 5.67 / 55.53 ± 5.63 0.288 / 0.233
Inferior disc 65.86 ± 6.27 / 65.97 ± 6.09 65.52 ± 8.65 / 65.55 ± 8.66 65.13 ± 4.38 / 65.13 ± 4.32 0.854 / 0.809
Temporal disc 55.18 ± 6.59 / 55.49 ± 5.15 56.04 ± 3.71 / 56.08 ± 3.67 53.81 ± 4.19 / 53.80 ± 4.13 0.336 / 0.228
Superior disc 64.23 ± 5.73 / 64.47 ± 5.41 64.50 ± 4.28 / 64.54 ± 4.30 64.07 ± 3.82 / 64.07 ± 3.83 0.882 / 0.936
Abbreviations: MS, multiple sclerosis; Std., standard; BCVA, best-corrected visual acuity; ON, optic neuritis. Asterisk marks significance based on ANOVA and
posterior post hoc Games-Howell test.
https://doi.org/10.1371/journal.pone.0243236.t005
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Table 6. Mean and standard deviation of vascular density. Average of the vascular density of the four macular quadrants. Best-corrected visual acuity and contrast sensi-
tivity in control subjects. MS group with EDSS of less than 3 and MS group with EDSS of more than 3.
CONTROLS MS EDSS < 3 MS EDSS� 3 P
Mean ± Std. deviation / (without
outliers)
Mean ± Std. deviation / (without
outliers)




N 151 56 30 –
BCVA 0.04 ± 0.07 0.04 ± 0.08 0.05 ± 0.1 0.930
Contrast sensitivity 1.84 ± 0.13 1.74 ± 0.16 1.76 ± 0.14 0.027�
Vascular density
(%)
Central macula 21.89 ± 4.80 / 21.78 ± 3.99 21.36 ± 4.82 / 21.39 ± 4.84 21.66 ± 4.08 / 21.67 ± 4.03 0.791 / 0.859
Nasal macula 48.21 ± 5.52 / 47.20 ± 3.13 46.22 ± 2.76 / 46.23 ± 2.80 47.03 ± 2.14 / 47.03 ± 2.11 0.024� / 0.126
Inferior macula 51.19 ± 5.8 / 49.84 ± 2.99 49.59 ± 3.69 / 49.63 ± 3.72 49.46 ± 3.46 / 49.53 ± 3.45 0.078 / 0.894
Temporal
macula
48.24 ± 4.21 / 47.73 ± 3.21 47.21 ± 2.31 / 47.21 ± 2.33 47.43 ± 2.72 / 47.40 ± 2.70 0.185 / 0.575
Superior
macula
51.53 ± 5.43 / 50.32 ± 3.17 49.29 ± 3.08 / 49.39 ± 3.07 49.76 ± 3.16 / 49.67 ± 3.21 0.006� / 0.148
Average 49.79 ± 4.72 48.08 ± 3.44 48.42 ± 3.09 0.057
Central disc 23.29 ± 12.80 / 23.32 ± 12.73 22.19 ± 11.96 / 22.20 ± 11.95 24.47 ± 11.89 / 24.42 ± 12.07 0.744 / 0.752
Nasal disc 57.98 ± 5.66 / 58.13 ± 5.46 57.67 ± 5.25 / 57.68 ± 5.21 55.19 ± 4.94 / 55.25 ± 5.09 0.053 / 0.038�
Inferior disc 65.86 ± 6.27 / 65.97 ± 6.09 66.48 ± 5.18 / 66.48 ± 5.18 62.72 ± 12.15 / 62.79 ± 12.16 0.064 / 0.061
Temporal disc 55.18 ± 6.59 / 55.49 ± 5.15 55.08 ± 4.11 / 55.11 ± 4.06 56.28 ± 3.30 / 56.33 ± 3.31 0.674 / 0.559
Superior disc 64.23 ± 5.73 / 64.47 ± 5.41 64.62 ± 4.37 / 64.64 ± 4.41 63.36 ± 4.45 / 63.37 ± 4.31 0.617 / 0.569
Abbreviations: MS, multiple sclerosis; Std., standard. Asterisk marks significance based on ANOVA and posterior post hoc Games-Howell test.
https://doi.org/10.1371/journal.pone.0243236.t006
Table 7. Spearman’s correlation between MSQoL-54 values and EDSS.
Spearman’s correlation EDSS Macular Disc
Central Nasal Inferior Temporal Superior Central Nasal Inferior Temporal Superior
MSQoL-MENT -0.478� 0.450� -0.204 -0.235 -0.044 -0.090 -0.162 -0.326 -0.110 -0.068 -0.095
DISTRESS -0.216 0.015 -0.066 -0.132 -0.239 -0.224 -0.079 0.273 0.257 -0.026 0.223
OVERALL -0.129 0.023 0.115 -0.002 -0.038 -0.254 -0.119 0.203 0.503� 0.086 0.343
EMOTIONAL -0.138 -0.06 0.053 -0.038 -0.181 -0.294 0.036 0.083 0.202 -0.013 0.080
MENTAL LIMIT -0.141 0.367 0.063 0.106 -0.274 -0.086 0.040 -0.019 0.234 0.307 -0.022
COGNITIVE -0.227 -0.289 0.122 0.010 0.049 -0.219 -0.062 0.277 0.216 -0.040 0.109
MSQoL-PHI -0.623�� 0.352 -0.296 -0.337 -0.038 -0.208 -0.081 -0.313 -0.126 -0.223 0.114
PHYSICAL -0.321 -0.011 -0.374 -0.229 -0.335 -0.336 0.122 0.051 0.062 -0.154 0.223
HEALTH PERCEP -0.157 -0.199 -0.172 -0.219 -0.174 -0.267 -0.063 -0.006 0.123 -0.100 0.180
ENERGY -0.253 -0.053 -0.016 -0.168 -0.357 -0.386 0.097 0.131 0.101 -0.100 0.0132
PHYSICAL LIMIT -0.467� 0.087 0.009 -0.126 -0.094 -0.359 0.307 0.213 0.240 -0.106 0.269
PAIN -0.040 -0.118 -0.110 -0.002 -0.132 -0.143 0.097 -0.057 0.144 0.134 0.087
SEXUAL FUNC -0.159 0.107 0.107 0.156 -0.053 -0.159 0.030 0.311 0.402 0.241 0.125
SOCIAL -0.161 -0.033 0.063 -0.026 -0.173 -0.286 -0.017 0.044 0.292 0.099 0.291
DISTRESS -0.216 0.015 -0.066 -0.132 -0.239 -0.224 -0.079 0.273 0.257 -0.026 0.223
CHANGE -0.455� 0.351 0.031 -0.116 -0.0147 -0.204 -0.203 0.115 0.184 -0.084 -0.101
SEX SATISF -0.157 0.314 -0.132 0.008 0.150 0.148 -0.091 0.065 0.364 0.228 0.178
Asterisk marks significance based on Bonferroni correction for multiple comparisons.
https://doi.org/10.1371/journal.pone.0243236.t007
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Discussion
Several studies have found that brain blood density is significantly affected in both early-diag-
nosed RRMS and primary progressive MS, indicating that this affectation is already present in
the early stages of the pathology [27,28]. Animal studies have shown that chronic hypoperfu-
sion of the brain can induce neurodegenerative changes, including the axonal degeneration so
characteristic of this disease [29].
In this study, a significant decrease in VD was observed in the superior, nasal and inferior mac-
ular areas in patients suffering from MS with Triton Plus OCTA. More precisely, VD decrease
remains significant when we remove outliers. Our results support previous research, such as Lan-
zillo R et al [12] (with Octovue OCTA device) and Olwen C Murphy et al [30] (Spectralis OCTA),
both showing a loss of VD in SVP macular ETDRS in MS patients. Only one study evidenced an
increase in VD in MS patients [31], which was realized with Angioplex Zeiss device.
Other studies as Garcı́a-Martı́n et al [32], conduct five-year follow-up of MS patients,
observed that the retinal nerve fiber layer and the ganglion cell layer measured in the peripapil-
lary ring are thinner in MS patients, especially in the temporal and superior areas. In light of
these results, it may be hypothesized that a relationship exists between the decrease in the tem-
poral and superior peripapillary RNFL and vasculature that nourishes this layer, especially in
superior macular area that shows a marked decrease in our results. Feucht et al [33] in his
study shows this with a high correlation between loss retinal vasculature and thinning retinal
layers. However, there are still very few published studies on OCT-A and MS, and it is still not
known whether retinal degeneration occurs due to the decrease in VD or whether it is an unre-
lated phenomenon that could precede the disease or occur simultaneously with it [34]. Follow-
up studies of MS patients could determine the relationship between neuronal loss and VD in
the retina. Other neurodegenerative diseases such as Alzheimer’s also produced similar
decreases in VD in the superficial plexus of the retina when measured using OCT-A, which
suggests that this test is able to detect ophthalmological impairments that occur in the course
of neurodegenerative diseases [35].
Our study shows that several macular areas present VD less in patients who have had the
disease for more than 5 years when compared with healthy subjects, indicating that the
advance of MS is reflected at the level of the superficial plexus of the retina in the form of mac-
ular level impairment. There was a strong negative correlation between the quality-of-life val-
ues and the EDSS score. At the same time, structural analysis by subgroup based on the EDSS
reveals that the group with scores of less than 3 exhibited less VD in the superior and nasal












Asterisk marks significance based on Bonferroni correction for multiple comparisons.
https://doi.org/10.1371/journal.pone.0243236.t008
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areas than healthy subjects. These results suggest that OCT-A is able to detect a reduction in
retinal VD in patients with a mild disability and that perhaps this vascular impairment is not
as marked in subjects with more severe cases of the disease. It would be revealing to evaluate
this test in subjects with clinically isolated syndrome and to observe whether OCT-A is able to
anticipate diagnosis of MS. There was, however, no significant correlation between either VD
and EDSS values or the quality-of-life questionnaire scores.
The results of this study show that retinal microvascularization is not impaired in patients
who have suffered episodes of optic neuritis when compared with patients who have not suf-
fered neuritis. However, contrast sensitivity is diminished after an episode of neuritis, as is
reported in the literature [36]. The sample of eyes with prior ON is small—just 20 affected eyes
—meaning that a study with a greater number of patients who have suffered this disease is
required. Structural disorders in these patients, highly evidenced in several studies, are related
to the inner layers of the retina, which leads to the hypothesis that VD in the intermediate lay-
ers is not affected by the inflammatory episode. Likewise, the macular area is not particularly
damaged by ON. Therefore, our results suggest, in line with other previous studies [37], that in
the course of MS the vascularization of the retina is not exclusively affected by inflammatory
lesion of the optic nerve, but rather by the disease itself.
Our study has some limitations. In OCT-A, proper segmentation and analysis of the vascu-
lar plexuses require high-quality images. This presents a challenge in patients with debilitating
diseases, especially in those suffering severe cognitive and physical impairments that make it
difficult for them to follow instructions and maintain concentration and this affected the small
sample size presented in this study. Additionally, the number of patients who answered
MSQoL-54 was small compared to the total sample. Another limitation is the fact that the
ETDRS grid needs to be positioned manually by the operator using the zone of minimum cen-
tral value for the VD as the point of reference. The study did not consider analyze immuno-
therapy treatment that patient taken which could alter the results. The optic disc presents a
wide range of anatomical variations within the parameters of normality. Therefore, although
patients with atypical eye characteristics were excluded, it should be noted that vascular data
may be conditioned by the characteristics of each optic nerve. We expose a retinal vessel den-
sity loss in FM patients without consider structural retinal state, this device does not measure
thickness in same mensuration of OCTA, but more information about thickness of the retinal
layers would complete the study.
In conclusion, our study shows that there is microvascular impairment in the perifoveal ret-
ina of MS patients. This decrease in VD is detectable in patients with mild functional
impairment and is most evident in those who have had the disease for longer. OCT-A is a
rapid, simple, non-invasive and easy-to-manage test that is useful in diagnosing the disease as
it flags decreased VD values even in patients with mild disabilities. Although the analysis area
is still small and we can only quantify the superficial plexus, the rapid development of optical
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